Indo US Bio-Tech Ltd. (IN:INDOUS)
:INDOUS
Want to see IN:INDOUS full AI Analyst Report?
Top Page
Indo US Bio-Tech Ltd.
(INDOUS)
Select Model
Select Model
Rating:51Neutral
Price Target:
₹96.00
▼(-11.11% Downside)
Action:N/A
Date:06/10/26
The score is held back primarily by weak cash generation and negative free cash flow combined with rising debt, despite strong reported revenue growth and a generally acceptable equity-backed balance sheet. Technical signals are also bearish (price below key moving averages with negative MACD and low RSI). Valuation is a relative support with a moderate P/E.
Positive Factors
Strong revenue growth
A 71.94% YoY revenue jump in FY2026 signals durable market traction for the company’s seeds and commercialization model. Sustained top-line growth supports scale in production, distribution and R&D, enabling long-term competitive positioning if margins are preserved.
Negative Factors
Negative operating & free cash flow
Sustained negative operating (~-126M) and free cash flow (~-150M) impair liquidity and force reliance on external funding. Over a multi-month horizon this can limit capacity to finance seed production cycles, dealer support and R&D, raising execution and growth risks.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
A 71.94% YoY revenue jump in FY2026 signals durable market traction for the company’s seeds and commercialization model. Sustained top-line growth supports scale in production, distribution and R&D, enabling long-term competitive positioning if margins are preserved.
Read all positive factors
Indo US Bio-Tech Ltd. (INDOUS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.79B
Dividend YieldN/A
Average Volume (3M)983.00
Price to Earnings (P/E)13.7
Beta (1Y)0.94
Revenue Growth6.36%
EPS Growth-19.37%
CountryIN
Employees883
SectorHealthcare
Sector Strength45
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)3.56
Shares Outstanding20,052,000
10 Day Avg. Volume961
30 Day Avg. Volume983
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.24
Price to Sales (P/S)1.87
P/FCF Ratio-13.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Indo US Bio-Tech Ltd. Business Overview & Revenue Model
Company Description
Indo Us Bio-Tech Ltd. is an Indian firm specializing in the entire seed value chain, encompassing production, processing, packaging, and distribution across India. Their diverse product lineup features an extensive selection of vegetable seeds, in...
How the Company Makes Money
Indo US Bio-Tech Ltd. primarily makes money by selling agricultural seeds to distributors/dealers and, directly or indirectly, to farmers. Revenue is generally generated from (1) sales of hybrid/varietal seeds across crop categories (e.g., field c...
Indo US Bio-Tech Ltd. Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
68
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 642.31M | 1.10B | 1.04B |
| Gross Profit | 143.60M | 301.69M | 294.70M |
| EBITDA | 88.39M | 170.66M | 2.23M |
| Net Income | 71.37M | 131.23M | 162.67M |
Balance Sheet | |||
| Total Assets | 1.17B | 1.33B | 978.43M |
| Cash, Cash Equivalents and Short-Term Investments | 5.88M | 69.13M | 2.48M |
| Total Debt | 276.43M | 370.36M | 148.36M |
| Total Liabilities | 305.44M | 405.63M | 193.24M |
| Stockholders Equity | 866.69M | 925.34M | 785.18M |
Cash Flow | |||
| Free Cash Flow | -83.36M | -149.89M | -100.69K |
| Operating Cash Flow | -74.56M | -125.81M | 91.00 |
| Investing Cash Flow | -34.90M | -15.00M | -7.92M |
| Financing Cash Flow | 104.92M | 199.56M | -14.77M |
Indo US Bio-Tech Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₹3.18B | 0.04 | ― | 1.26% | 21.98% | 5.46% | |
60 Neutral | ₹18.55B | 15.47 | ― | 0.43% | 27.62% | 43.94% | |
53 Neutral | ₹3.83B | 7.65 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ₹1.79B | 13.67 | ― | ― | 6.36% | -19.37% | |
48 Neutral | ₹5.60B | 63.22 | ― | 0.78% | -30.74% | -87.31% | |
47 Neutral | ₹17.14B | -21.20 | ― | ― | 17.53% | 43.42% |
* Healthcare Sector Average
IN:INDOUS
Indo US Bio-Tech Ltd.
89.35
-61.95
-40.95%
IN:ASTEC
Astec Lifesciences Limited
769.00
-26.05
-3.28%
IN:BESTAGRO
Best Agrolife Ltd.
15.78
-5.72
-26.61%
IN:IPL
India Pesticides Ltd.
161.05
-46.02
-22.22%
IN:NATHBIOGEN
Nath Bio-Genes (India) Ltd.
167.25
-33.83
-16.82%
IN:IGCL
Indogulf Cropsciences Limited
60.51
-47.14
-43.79%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.